title: Hospitalisation for RSV infection in ex-preterm infants-implications for use of RSV immune globulin.
abstract: BACKGROUND
  Respiratory syncytial virus (RSV) specific immune globulin is now being marketed for prevention of RSV infection in ex-preterm infants. However, there are no published UK data on the morbidity or mortality from RSV in these infants.
  
  
  OBJECTIVE
  To determine the morbidity and mortality from RSV infection in a cohort of infants previously treated at a regional neonatal unit, and compare the cost of hospitalisation for RSV with the potential cost of administering RSV immune globulin (RSV-IG) prophylaxis.
  
  
  METHODS
  Infants born at a gestation of less than 32 weeks were studied. Details of admissions for respiratory illness in the first two years of life were collected from hospital records, referring hospitals, and general practitioners.
  
  
  RESULTS
  Data on 82 infants were collected. Up to three RSV seasons were encountered. The hospitalisation rate for confirmed RSV infection for the first season encountered was 4%. Rates of ward and paediatric intensive care unit admission were higher for infants with chronic lung disease. There were no deaths from RSV. RSV-IG would not have been cost effective for most infants.
  
  
  CONCLUSIONS
  The morbidity and mortality rates from RSV observed in this group do not support the widespread introduction of RSV-IG prophylaxis for ex-preterm infants.
authors.affiliation: Neonatal Unit, St George's Hospital, Blackshaw Road, London SW17 0QT, UK.
authors.forename: M
authors.initials: M
authors.lastname: Thomas
authors.forename: A
authors.initials: A
authors.lastname: Bedford-Russell
authors.forename: M
authors.initials: M
authors.lastname: Sharland
mesh_terms: D000911:Antibodies, Monoclonal / Q000191:economics / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents / Q000191:economics / Q000627:therapeutic use; D015331:Cohort Studies; D003362:Cost-Benefit Analysis; D017048:Health Care Costs; D006760:Hospitalization / Q000191:economics; D006801:Humans; D007116:Immunization, Passive / Q000191:economics*; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D007231:Infant, Newborn; D007234:Infant, Premature; D000069455:Palivizumab; D010343:Patient Admission / Q000706:statistics & numerical data; D018357:Respiratory Syncytial Virus Infections / Q000191:economics / Q000453:epidemiology / Q000517:prevention & control*; D012136:Respiratory Syncytial Viruses / Q000276:immunology; D006113:United Kingdom / Q000453:epidemiology
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents; D016756:Immunoglobulins, Intravenous; D000069455:Palivizumab